Group 1 - The core viewpoint of the news is that Spring Medical has seen a stock price increase of 5.42%, reaching 26.06 CNY per share, with a total market capitalization of 9.996 billion CNY as of the report date [1] - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [1] - The company's revenue composition is primarily from medical device products, accounting for 99.89%, with a minor contribution from other sources at 0.11% [1] Group 2 - Among the top circulating shareholders of Spring Medical, a fund under China Europe Fund, specifically the China Europe Prosperity Selected Mixed A (020876), has entered the top ten shareholders, holding 2.8326 million shares, which is 0.74% of the circulating shares [2] - The China Europe Prosperity Selected Mixed A fund has achieved a year-to-date return of 7.47% and a one-year return of 63.55%, ranking 1811 out of 8836 and 1302 out of 8091 respectively [2] - The fund manager, Zhang Xueming, has been in position for 1 year and 266 days, with the fund's total asset size at 6.741 billion CNY and a best return of 79% during his tenure [3]

Group 1 - The core viewpoint of the news is that Spring Medical has shown a positive stock performance with a year-to-date increase of 12.04% and significant growth in revenue and net profit for the first nine months of 2025 [2][3]. - As of January 13, Spring Medical's stock price was 25.40 CNY per share, with a market capitalization of 9.743 billion CNY and a trading volume of 41.034 million CNY [1]. - The company specializes in the research, production, and sales of orthopedic medical devices, primarily focusing on joint prosthetics and spinal implants, with a revenue composition of 99.89% from medical device products [2]. Group 2 - For the first nine months of 2025, Spring Medical achieved a revenue of 756 million CNY, representing a year-on-year growth of 48.75%, and a net profit of 192 million CNY, which is a 213.21% increase compared to the previous year [3]. - The company has distributed a total of 440 million CNY in dividends since its A-share listing, with 390 million CNY distributed over the last three years [4]. - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [3].

声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 针对上述提问，春立医疗回应称："尊敬的投资者，您好！国际化战略是公司发展的核心驱动力之一。 公司积极推进海外市场布局。目前，公司产品已销往全球多个国家和地区，其中包括欧盟成员国。感谢 您的关注！" 有投资者在互动平台向春立医疗提问："请问近两年是否出口欧盟国家？" ...

Company Overview - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [1][2] - The company was established on February 12, 1998, and went public on December 30, 2021 [1] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [1] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75% [2] - The net profit attributable to the parent company for the same period was 192 million yuan, showing a significant year-on-year increase of 213.21% [2] - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] Stock Performance - As of January 12, 2025, Spring Medical's stock price was 24.45 yuan per share, with a year-to-date increase of 7.85% [1] - The stock experienced a slight decline of 2.16% on the same day, with a trading volume of 871.39 million yuan and a turnover rate of 0.12% [1] - The company has seen a net inflow of 555,100 yuan from main funds, with large orders accounting for 16.81% of total purchases [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2] - Notable new shareholders include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed A Fund, which are now among the top ten circulating shareholders [3]

Company Overview - Spring Medical is a Chinese company primarily engaged in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The company was established on February 12, 1998, and went public on December 30, 2021 [2] - Its main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [2] Financial Performance - For the period from January to September 2025, Spring Medical achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75% [2] - The net profit attributable to the parent company was 192 million yuan, showing a significant year-on-year increase of 213.21% [2] Shareholder Information - As of September 30, 2025, the number of shareholders for Spring Medical was 6,164, an increase of 4.12% compared to the previous period [2] - The average number of circulating shares per shareholder was 46,906, which decreased by 3.95% from the previous period [2] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 2.9585 million shares as a new shareholder [3] - The fifth-largest circulating shareholder, China Europe Economic Selection Mixed A, held 2.8326 million shares, also as a new shareholder [3] - The eighth-largest circulating shareholder, Ping An Low Carbon Economy Mixed A, reduced its holdings by 1.67 million shares [3] Financing and Margin Trading - On January 8, Spring Medical's stock price fell by 2.50%, with a trading volume of 68.9415 million yuan [1] - The financing buy-in amount for the day was 7.91 million yuan, with a net buy of 4.8332 million yuan after repayments [1] - The total margin trading balance was 37.0622 million yuan, with the financing balance accounting for 0.51% of the circulating market value, indicating a high level compared to the past year [1]

中国经济网北京1月8日讯 春立医疗(688236.SH)今日收报25.00元，跌幅2.50%。目前该股处于破发 状态。 春立医疗于2021年12月30日在上交所科创板上市，发行价格为29.81元，发行股份数量3,842.80万 股，保荐机构为华泰联合证券有限责任公司，保荐代表人为张畅、茹涛。 春立医疗上市发行募集资金总额为114,553.87万元，扣除发行费用后募集资金净额为106,712.83万 元，较原拟募集资金净额少93287.17万元。 2021年12月27日，春立医疗发布的招股书显示，公司拟募集资金200,000.00万元，用于骨科植入物 及配套材料综合建设项目、研发中心建设项目、营销网络建设项目、补充流动资金项目。 春立医疗上市发行费用合计7,841.04万元，华泰联合证券有限责任公司获得保荐费用150.00万元、 承销费用6,523.59万元。 (责任编辑：魏京婷) ...

Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong performance in the orthopedic medical device sector [1][2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [1]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [1]. - The non-recurring net profit was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [1]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable rise of 109.51% year-on-year [1]. - The net profit for Q3 2025 was 77.06 million yuan, showing a staggering increase of 531.12% year-on-year [1]. - The non-recurring net profit for Q3 2025 was 74.52 million yuan, up 439.4% year-on-year [1]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [1]. - The gross profit margin is reported at 67.27% [1]. Market Activity - As of January 7, 2026, the stock closed at 25.64 yuan, with a slight increase of 0.31% [1]. - The turnover rate was 0.62%, with a trading volume of 18,000 hands and a transaction amount of 46.3441 million yuan [1]. - On January 7, the net inflow of main funds was 159,600 yuan, accounting for 0.34% of the total transaction amount [1]. - Retail investors experienced a net outflow of 201,990 yuan, representing 4.36% of the total transaction amount [1]. - Over the past 90 days, 8 institutions have rated the stock as a buy, with an average target price of 31.7 yuan [2].

北京市春立正达医疗器械股份有限公司提交截至2025年12月31日的证券变动月报表，报告显示公司H股 和A股的法定股本、已发行股份及库存股数量均无变动。H股于香港联交所上市，A股于上海证券交易 所上市。截至月底，H股法定股份为95,140,500股，A股法定股份为288,428,000股，总注册资本为人民币 383,568,500元。已发行股份总数未发生变化，库存股数量保持不变。 交易信息汇总 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向 1月6日主力资金净流入306.99万元；游资资金净流入80.45万元；散户资金净流出387.44万元。 截至2026年1月6日收盘，春立医疗(688236)报收于25.56元，上涨2.61%，换手率1.14%，成交量3.29万 手，成交额8275.97万元。 公司公告汇总 当日关注点 H股市场公告 来自交易信息汇总：1月6日主力资金净流入306.99万元，显示主力对个股短期态度偏积极。 来自公司公告汇总：春立医疗提交截至2025年12月31日证券变动月报表，H股与A股股本结构无变 化。 ...

Core Viewpoint - Spring Medical (688236) has shown significant growth in revenue and net profit, indicating strong performance in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit after deducting non-recurring items was 181 million yuan, reflecting a 311.07% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable increase of 109.51% year-on-year [2]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, up 531.12% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 74.52 million yuan, an increase of 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 5, 2026, the stock closed at 24.91 yuan, with an increase of 8.87% [1]. - The turnover rate was 1.27%, with a trading volume of 36,600 hands and a transaction amount of 88.41 million yuan [1]. - On January 5, the net outflow of main funds was 3.2551 million yuan, accounting for 3.68% of the total transaction amount [1]. - Retail investors saw a net inflow of 3.7834 million yuan, representing 4.28% of the total transaction amount [1]. Institutional Ratings - In the last 90 days, 8 institutions have given buy ratings for the stock, with an average target price of 31.7 yuan [3].

Core Viewpoint - Spring Medical experienced a slight decline in stock price on December 31, with a trading volume of 24.47 million yuan, indicating a potential shift in investor sentiment and market dynamics [1] Financing Summary - On December 31, Spring Medical had a financing buy-in amount of 1.23 million yuan and a financing repayment of 1.39 million yuan, resulting in a net financing outflow of 0.15 million yuan [1] - The total financing and securities lending balance for Spring Medical reached 38.24 million yuan, with the financing balance accounting for 0.58% of the circulating market value, which is above the 70th percentile level over the past year, indicating a relatively high position [1] - The securities lending aspect showed no shares were repaid or sold on December 31, with a remaining securities lending volume of 200 shares and a balance of 4,576 yuan, also exceeding the 80th percentile level over the past year [1] Company Overview - Beijing Spring Medical Equipment Co., Ltd. was established on February 12, 1998, and went public on December 30, 2021, focusing on the research, production, and sales of implantable orthopedic medical devices [2] - The company's main products include joint prosthetics and spinal implant products, covering major human joints such as hip, knee, shoulder, and elbow, with a comprehensive range of spinal fixation systems [2] - As of September 30, Spring Medical reported a revenue of 756 million yuan for the first nine months of 2025, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Dividend and Shareholder Information - Since its A-share listing, Spring Medical has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Notable institutional shareholders include Hong Kong Central Clearing Limited as the fourth largest shareholder with 2.96 million shares, and new entrants like China Europe Economic Growth Mixed A Fund and Ping An Low Carbon Economy Mixed A Fund [3]